{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:21:52Z","timestamp":1789924912673,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023322","name":"University of Szeged Albert Szent-Gy\u00f6rgyi Faculty of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ijcard.2025.133882","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:51:29Z","timestamp":1757170289000},"page":"133882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Mavacamten effectively reduces\u00a0>\u00a0100\u00a0mmHg left ventricular outflow tract gradients as early as one week of treatment in obstructive hypertrophic cardiomyopathy"],"prefix":"10.1016","volume":"442","author":[{"given":"Vikt\u00f3ria","family":"Nagy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"R\u00e1cz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedvig","family":"Tak\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Boda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianka","family":"Polestyuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mi","family":"Schvartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3 D\u00e1niel","family":"Vid\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen\u0151 Antal","family":"Pint\u00e9r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"P\u00e1link\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1rp\u00e1d","family":"Korm\u00e1nyos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Sz\u0171csborus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"Borb\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Szili-T\u00f6r\u00f6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00f3bert","family":"Sepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2025.133882_bb0005","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1080\/13543784.2020.1821361","article-title":"Mavacamten: a novel small molecule modulator of beta-cardiac myosin for treatment of hypertrophic cardiomyopathy","volume":"29","author":"Tower-Rader","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ijcard.2025.133882_bb0010","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human beta-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ijcard.2025.133882_bb0015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.hfc.2017.12.004","article-title":"Genetic pathogenesis of hypertrophic and dilated cardiomyopathy","volume":"14","author":"Garfinkel","year":"2018","journal-title":"Heart Fail. Clin."},{"key":"10.1016\/j.ijcard.2025.133882_bb0020","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2025.133882_bb0025","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2025.133882_bb0030","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Garcia-Pavia","year":"2024","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2025.133882_bb0035","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1161\/CIRCULATIONAHA.124.072445","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 128 results from VALOR-HCM","volume":"151","author":"Desai","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2025.133882_bb0040","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s40265-022-01739-7","article-title":"Mavacamten: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ijcard.2025.133882_bb0045","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1093\/eurheartj\/ehad429","article-title":"The European medicines agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients","volume":"44","author":"DeVries","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2025.133882_bb0050","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2025.133882_bb0055","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the Management of Hypertrophic Cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on clinical practice guidelines","volume":"83","author":"Writing Committee","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2025.133882_bb0060","unstructured":"Squibb BM. Full Prescribing Information (CAMZYOS). Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214998 s000lbl.pdf. Accessed August 2, 2024."},{"key":"10.1016\/j.ijcard.2025.133882_bb0065","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/ehjci\/jead236","article-title":"Non-invasive estimation of left ventricular systolic peak pressure: a prerequisite to calculate myocardial work in hypertrophic obstructive cardiomyopathy","volume":"25","author":"Batzner","year":"2024","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"10.1016\/j.ijcard.2025.133882_bb0070","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/ehjci\/jey188","article-title":"Echocardiographic reference ranges for normal non-invasive myocardial work indices: results from the EACVI NORRE study","volume":"20","author":"Manganaro","year":"2019","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"10.1016\/j.ijcard.2025.133882_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100710","article-title":"Mavacamten short-term hemodynamic, functional, and electrocardiographic outcomes: initial real-world post-trial experience","volume":"2","author":"Abdelfattah","year":"2023","journal-title":"JACC Adv."},{"key":"10.1016\/j.ijcard.2025.133882_bb0080","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ehf2.14882","article-title":"Mavacamten in real-life practice: initial experience at a hypertrophic cardiomyopathy Centre","volume":"12","author":"Abood","year":"2025","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.ijcard.2025.133882_bb0085","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011188","article-title":"Long-term effects of Mavacamten on electromechanical dispersion and deformation in obstructive hypertrophic cardiomyopathy","volume":"17","author":"Del Franco","year":"2024","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ijcard.2025.133882_bb0090","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.034069","article-title":"Eighteen-month real-world experience using Mavacamten for treatment of obstructive hypertrophic cardiomyopathy in a racially diverse population","volume":"13","author":"Ramonfaur","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2025.133882_bb0095","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jchf.2024.03.009","article-title":"Real-world experience and 36-week outcomes of patients with symptomatic obstructive hypertrophic cardiomyopathy treated with Mavacamten","volume":"12","author":"Reza","year":"2024","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ijcard.2025.133882_bb0100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pcad.2024.02.001","article-title":"Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: observations from a tertiary care center","volume":"86","author":"Desai","year":"2024","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.ijcard.2025.133882_bb0105","first-page":"11","article-title":"Myocardial work: methodology and clinical applications","author":"Papadopoulos","year":"2021","journal-title":"Diagnostics (Basel)."},{"issue":"Suppl. S2","key":"10.1016\/j.ijcard.2025.133882_bb0110","first-page":"426","article-title":"Characterisation of interrelations among myocardial work parameters in patients with hypertrophic cardiomyopathy: differences between non-obstructive and obstructive disease","volume":"27","author":"Kormanyos","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2025.133882_bb0115","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.hrthm.2024.04.055","article-title":"Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with Mavacamten","volume":"21","author":"Castrichini","year":"2024","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.ijcard.2025.133882_bb0120","article-title":"Incidence and recurrence of atrial fibrillation among patients with obstructive hypertrophic cardiomyopathy treated with mavacamten: a single-center experience","author":"Liang","year":"2024","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.ijcard.2025.133882_bb0125","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jacep.2024.10.014","article-title":"Atrial fibrillation in patients receiving Mavacamten for obstructive hypertrophic cardiomyopathy: real-world incidence, management, and outcomes","volume":"11","author":"Boyle","year":"2025","journal-title":"JACC Clin. Electrophysiol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527325009258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527325009258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T16:32:01Z","timestamp":1780763521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527325009258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":25,"alternative-id":["S0167527325009258"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2025.133882","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mavacamten effectively reduces\u00a0>\u00a0100\u00a0mmHg left ventricular outflow tract gradients as early as one week of treatment in obstructive hypertrophic cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2025.133882","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"133882"}}